Vikram Aditya Shankar, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 30
- 8 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · Bdhv Medical Group of California PC
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
30 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shankar’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
30 of 30 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A178759 · Current
Licensed to practise in California · since 2022 · expires 2028-05-31 · Washington University in St. Louis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$164,001
Medicare paid this office $164,001 for 670 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient problem focused exam of visual system | 323 | $42,183 | $85 |
| Established patient complete exam of visual system | 288 | $30,098 | $98 |
| Removal of cataract with insertion of prosthetic lens | 24 | $18,461 | $527 |
| New patient complete exam of visual system | 119 | $11,357 | $95 |
| Removal of recurring cataract in lens capsule using a laser | 23 | $7,952 | $346 |
See all 15 services
| Established patient problem focused exam of visual system | 323 | $42,183 | $85 |
| Established patient complete exam of visual system | 288 | $30,098 | $98 |
| Removal of cataract with insertion of prosthetic lens | 24 | $18,461 | $527 |
| New patient complete exam of visual system | 119 | $11,357 | $95 |
| Removal of recurring cataract in lens capsule using a laser | 23 | $7,952 | $346 |
| Exam of visual field with extended testing | 112 | $7,122 | $62 |
| Imaging of retina | 181 | $5,961 | $32 |
| Imaging of optic nerve | 165 | $5,746 | $34 |
| Measurement of corneal curvature and depth of eye | 70 | $5,085 | $45 |
| Ct scan of cornea | 36 | $1,523 | $34 |
| Exam of the internal drainage system of eye | 40 | $1,117 | $27 |
| New patient problem focused exam of visual system | 19 | $988 | $52 |
| Ultrasound scan of cornea to determine thickness | 73 | $760 | $10 |
| Ultrasound scan to determine eye length and lens power | 13 | $679 | $49 |
| Photography of the retina | 20 | $541 | $27 |
Procedures Medicare counted
| Cataract surgery | 179 | More than 82% of doctors who do this |
Who their Medicare patients are
670 Original Medicare patients in 2024. Average age 77 · Under 65 4% · 85 and older 19% · Women 59% · Also on Medicaid 40% · Health risk score 1.22. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 39% · Coronary heart disease 33% · Chronic kidney disease 23% · Atrial fibrillation 18% · Cancer 17% · Heart failure 16% · Depression 13% · COPD 10% · Stroke 10% · Dementia 6%.
The office billed $516,585, Medicare allowed $226,313 and paid $164,001; for 1,856 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 670 | 1,856 | 77 | 1.22 | $516,585 | $164,001 |
| 2023 | 268 | 422 | 75 | 1.24 | $106,005 | $37,790 |
| 2022 | 72 | 88 | 75 | 1.19 | $53,349 | $4,205 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Established patient complete exam of visual system | 100 | $11,948 | $118 |
| New patient complete exam of visual system | 47 | $6,338 | $135 |
| Established patient problem focused exam of visual system | 44 | $4,400 | $85 |
| Short return visit (20+ min) | 39 | $2,074 | $52 |
| Imaging of optic nerve | 43 | $1,213 | $28 |
| Photography of the retina | 35 | $1,157 | $33 |
| Ultrasound scan to determine eye length and lens power | 14 | $962 | $69 |
| Imaging of retina | 19 | $654 | $34 |
| Exam of visual field with extended testing | 15 | $552 | $37 |
| Ultrasound scan of cornea to determine thickness | 13 | $124 | $10 |
2022: 3 services
| Short return visit (20+ min) | 14 | $846 | $60 |
| Measurement of corneal curvature and depth of eye | 15 | $428 | $29 |
| Imaging of retina | 15 | $354 | $24 |
Medicaid work
$92,233 in 2024
Medicaid paid $92,233 for 1,119 billed services this clinician did in 2024, up to 76 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 288 | $33,044 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 213 | $28,339 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 253 | $20,504 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 83 | $3,372 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 89 | $2,750 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 39 | $2,018 |
| INTRM OPH EXAM NEW PATIENT | 12 | $1,096 |
| Ophthalmic biometry by A-scan ultrasound echography with intraocular lens power calculation | 16 | $784 |
| DETERMINATION REFRACTIVE STATE | 126 | $326 |
| 2024 | 1,119 | 9 | 76 | $92,233 |
| 2023 | 582 | 8 | 47 | $43,014 |
See the largest Medicaid services in earlier years
2023
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 163 | $15,536 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 109 | $12,731 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 127 | $10,053 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 50 | $1,305 |
| INTRM OPH EXAM NEW PATIENT | 15 | $1,068 |
| Ophthalmic biometry by A-scan ultrasound echography with intraocular lens power calculation | 14 | $805 |
| DETERMINATION REFRACTIVE STATE | 78 | $803 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 26 | $713 |
Drugs they prescribed that Part D paid
$86,642
Pharmacies billed $86,642 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 990) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
546 generic and 444 brand-name prescriptions · $86,642 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 26 | $13,284 | $511 |
| Vyzulta | 22 | $11,132 | $506 |
| Rhopressa | 16 | $6,614 | $413 |
| Cyclosporine | 15 | $6,041 | $403 |
| Brimonidine | 76 | $4,623 | $61 |
See all 14 drugs
| Restasis | 26 | $13,284 | $511 |
| Vyzulta | 22 | $11,132 | $506 |
| Rhopressa | 16 | $6,614 | $413 |
| Cyclosporine | 15 | $6,041 | $403 |
| Brimonidine | 76 | $4,623 | $61 |
| Prednisolone Acetate | 91 | $3,182 | $35 |
| Latanoprost | 312 | $3,131 | $10 |
| Dorzolamide-Timolol | 13 | $2,865 | $220 |
| Dorzolamide-Timolol | 97 | $2,079 | $21 |
| Timolol Maleate | 102 | $1,417 | $14 |
| Erythromycin | 42 | $409 | $10 |
| Dorzolamide | 18 | $319 | $18 |
| Ketorolac Tromethamine | 18 | $316 | $18 |
| Ofloxacin | 19 | $253 | $13 |
Year by year
| 2024 | 990 | 364 | 0% (0) | 45% | $86,642 |
| 2023 | 1,850 | 531 | None | 49% | $300,969 |
| 2022 | 964 | 369 | 0% (0) | 44% | $98,915 |
| 2021 | 706 | 222 | 0% (0) | 37% | $40,564 |
| 2020 | 374 | 172 | 0% (0) | 24% | $18,484 |
| 2019 | 129 | 68 | 0% (0) | None | $7,445 |
| 2018 | 51 | 22 | 0% (0) | None | $3,847 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 27 drugs
| Restasis | 58 | $42,010 | $724 |
| Rhopressa | 74 | $38,458 | $520 |
| Lumigan | 50 | $23,735 | $475 |
| Brinzolamide | 52 | $21,927 | $422 |
| Alphagan P | 14 | $14,733 | $1,052 |
| Brimonidine | 136 | $13,278 | $98 |
| Travoprost | 41 | $12,967 | $316 |
| Rocklatan | 22 | $11,905 | $541 |
| Combigan | 24 | $11,206 | $467 |
| Vyzulta | 22 | $10,765 | $489 |
| Simbrinza | 39 | $10,512 | $270 |
| Latanoprost | 557 | $9,316 | $17 |
| Cyclosporine | 21 | $8,691 | $414 |
| Azopt | 20 | $7,952 | $398 |
| Zioptan | 15 | $6,968 | $465 |
| Dorzolamide-Timolol | 28 | $5,166 | $185 |
| Brimonidine Tartrate-Timolol | 16 | $5,089 | $318 |
| Prednisolone Acetate | 77 | $4,279 | $56 |
| Difluprednate | 25 | $3,987 | $159 |
| Timolol Maleate | 149 | $3,882 | $26 |
| Dorzolamide-Timolol | 126 | $3,503 | $28 |
| Tafluprost | 17 | $2,867 | $169 |
| Dorzolamide | 69 | $2,316 | $34 |
| Erythromycin | 53 | $751 | $14 |
| Ketorolac Tromethamine | 18 | $496 | $28 |
| Moxifloxacin | 11 | $407 | $37 |
| Ofloxacin | 14 | $286 | $20 |
2022: 15 drugs
| Lumigan | 22 | $11,757 | $534 |
| Restasis | 19 | $11,191 | $589 |
| Rhopressa | 21 | $9,752 | $464 |
| Prednisolone Acetate | 170 | $7,938 | $47 |
| Brimonidine | 67 | $5,809 | $87 |
| Rocklatan | 12 | $3,931 | $328 |
| Latanoprost | 176 | $2,983 | $17 |
| Dorzolamide-Timolol | 69 | $2,329 | $34 |
| Ketorolac Tromethamine | 69 | $2,000 | $29 |
| Timolol Maleate | 44 | $1,317 | $30 |
| Moxifloxacin | 16 | $637 | $40 |
| Erythromycin | 50 | $579 | $12 |
| Dorzolamide | 18 | $544 | $30 |
| Atropine Sulfate | 11 | $458 | $42 |
| Polymyxin B Sul-Trimethoprim | 44 | $390 | $9 |
2021: 9 drugs
| Brimonidine | 74 | $7,864 | $106 |
| Prednisolone Acetate | 110 | $4,324 | $39 |
| Dorzolamide-Timolol | 74 | $2,349 | $32 |
| Latanoprost | 132 | $2,168 | $16 |
| Ketorolac Tromethamine | 41 | $1,157 | $28 |
| Erythromycin | 56 | $749 | $13 |
| Polymyxin B Sul-Trimethoprim | 48 | $475 | $10 |
| Bacitracin-Polymyxin | 16 | $241 | $15 |
| Timolol Maleate | 13 | $165 | $13 |
2020: 10 drugs
| Brimonidine | 28 | $2,532 | $90 |
| Dorzolamide-Timolol | 30 | $1,129 | $38 |
| Prednisolone Acetate | 28 | $879 | $31 |
| Latanoprost | 68 | $846 | $12 |
| Erythromycin | 43 | $539 | $13 |
| Valacyclovir | 19 | $537 | $28 |
| Bacitracin-Polymyxin | 25 | $377 | $15 |
| Polymyxin B Sul-Trimethoprim | 16 | $147 | $9 |
| Neomycin-Polymyxin-Dexameth | 11 | $144 | $13 |
| Cyclopentolate | 11 | $123 | $11 |
2019: 1 drug
| Erythromycin | 20 | $256 | $13 |
Money from drug and device companies
$112 in 2025
| 2025 | 2 | 5 | None | $112 |
| 2024 | 4 | 7 | None | $148 |
| 2023 | 5 | 8 | None | $301 |
| 2022 | 2 | 8 | None | $617 |
| 2021 | 1 | 2 | None | $83 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Tepezza | $92 | 4 payments
|
| Bausch & Lomb Americas | Vyzulta | $19 | 1 payment
|
See all 5 published payments
| Amgen | Meals · 2025-12-04 | Tepezza | $24 |
| Amgen | Meals · 2025-08-18 | Tepezza | $23 |
| Bausch & Lomb Americas | Meals · 2025-04-14 | Vyzulta | $19 |
| Amgen | Meals · 2025-03-26 | Tepezza | $22 |
| Amgen | Meals · 2025-02-19 | Tepezza | $23 |
See earlier years (2024, 2023, 2022, 2021)
2024: $148
| Amgen | Tepezza | $60 | 3 payments
|
| Alcon Vision | Hydrus Microstent | $48 | 2 payments
|
| Sight Sciences | Omni Surgical System | $21 | 1 payment
|
| Bausch & Lomb Americas | Vyzulta | $20 | 1 payment
|
2023: $301
| Johnson & Johnson Surgical Vision | Tecnis Iol | $105 | 2 payments
|
| Alcon Vision | Hydrus Microstent | $93 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $44 | 2 payments
|
| Glaukos | Istent Inject Trabecular Micro-Bypass System | $42 | 2 payments
|
| Thea Pharma | Iyuzeh | $18 | 1 payment
|
2022: $617
| Alcon Vision | Clareon | $560 | 7 payments
|
| Sight Sciences | Omni(R) Surgical System (US) | $57 | 1 payment
|
2021: $83
| Alcon Vision | Acrysof | $83 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1891298634
- Licence
- CA A178759California A178759: Current · expires 2028-05-31
- Trained
- Washington University School of Medicine, 2018
- Group
- Stanford Health Care · Bdhv Medical Group of California PC
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0009X (207WX0009X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2018-03-16
- NPI last updated
- 2024-07-09
- NPI record certified
- 2024-07-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 800 Spruce St, Philadelphia, PA, 19107 · 840 Walnut St, Philadelphia, PA, 19107